Shaw Peter H, Reed Damon R, Yeager Nicholas, Zebrack Bradley, Castellino Sharon M, Bleyer Archie
*Department of Pediatrics, Children's Hospital of Pittsburgh of UPMC, University of Pittsburgh School of Medicine, Pittsburgh, PA †Sarcoma Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL ‡Division of Pediatric Hematology/Oncology, Nationwide Children's Hospital, The Ohio State University, Columbus, OH §University of Michigan School of Social Work, Ann Arbor, MI ∥Department of Pediatrics, Section on Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, NC ¶Quality Department, St Charles Health System, Bend, OR.
J Pediatr Hematol Oncol. 2015 Apr;37(3):161-9. doi: 10.1097/MPH.0000000000000318.
Over the last 30 years, it has become apparent that oncology patients ages 15 to 39 have not reaped the same rewards of improved survival that we have seen in younger and older patients. As a result, in 2006 the Adolescent and Young Adult (AYA) Oncology Progress Review Group convened and examined the factors that impact the care of the 70,000 new cases per year (approximately 7% of all new cases) in the United States and published their findings. The reasons for inferior survival gains are of course multiple and include the settings in which patients are cared for, clinical trial enrollment, insurance coverage, varied treatment of sarcomas, varied treatment of acute lymphoblastic leukemia, the psychosocial impact of cancer and cancer survivorship. A new area of a yet-to-be completely defined subspecialty was born out of this meeting: AYA oncology. As a medical community we realized that these patients do not fit neatly into the pediatric nor adult world and, therefore, require a unique approach which many individuals, oncology centers, advocacy groups, and cooperative trial groups have started to address. This group of dedicated providers and advocates has made strides but there is still much work to be done on the local, national, and international level to make up for shortcomings in the medical system and improve outcomes. We review key components of AYA cancer care in 2015 that all providers should be aware of, how far we have come, where this movement is headed, and the obstacles that continue to stand in the way of better cure rates and quality of life after cure for this unique group of patients. Like an adolescent maturing into adulthood, this movement has learned from the past and is focused on moving into the future to achieve its goals.
在过去30年里,有一点已变得很明显,即15至39岁的肿瘤患者并未像我们在更年轻和更年长的患者身上看到的那样,从生存率提高中获得同样的益处。因此,2006年青少年及青年成人(AYA)肿瘤学进展审查小组召开会议,研究影响美国每年70000例新病例(约占所有新病例的7%)治疗的因素,并公布了他们的研究结果。生存率提高较少的原因当然是多方面的,包括患者接受治疗的环境、临床试验入组情况、保险覆盖范围、肉瘤的不同治疗方法、急性淋巴细胞白血病的不同治疗方法、癌症的心理社会影响以及癌症幸存者问题。这次会议催生了一个尚未完全明确的亚专业新领域:AYA肿瘤学。作为一个医学界,我们意识到这些患者既不完全适合儿科领域,也不完全适合成人领域,因此需要一种独特的方法,许多个人、肿瘤中心、倡导团体和合作试验团体已经开始着手解决这个问题。这群敬业的医疗服务提供者和倡导者已经取得了进展,但在地方、国家和国际层面仍有许多工作要做,以弥补医疗系统的不足并改善治疗效果。我们回顾2015年AYA癌症治疗的关键组成部分,所有医疗服务提供者都应了解这些内容,我们已经取得了多大的进展,这一行动的方向,以及仍然阻碍这一独特患者群体提高治愈率和治愈后生活质量的障碍。就像一个青少年成长为成年人一样,这一行动从过去吸取了教训,并专注于迈向未来以实现其目标。